Azilect (Teva) is a pure isomer of rasagiline and is the most recent selective irreversible monoamine oxidase inhibitor to enter the market. Azilect prolongs the activity of dopamine in the brain to restore a measure of normal locomotion, gait, and coordination. Rasagiline is believed to be five to 10 times more potent at inhibiting the monoamine oxidase B enzyme than selegiline. In contrast to selegiline, Azilect has a cleaner side-effect profile as it does not metabolize into amphetamine derivatives.
Sales for Teva's monoamine oxidase B (MAO-B) inhibitor Azilect (rasagiline) continue to build momentum, with approvals across all Parkinson's disease severities. Although the much-touted neuroprotective indication for Azilect was rejected by the US Food and Drug Administration (FDA) in 2012, line and geographic expansions will propel the drug towards market leadership until genericization and pipeline candidates such as Newron Pharmaceuticals' Xadago (safinamide) begin to erode Azilect's patient share. Teva has noted that the 11% increase in global revenues of Azilect to $549m in 2014 was due to increased prices and demand for the drug in the US and EU.
Key Topics Covered:
1 Product Profiles
2 Azilect: Parkinson's disease
List of Figures
Figure 1: Azilect (rasagiline; Teva/Lundbeck/Takeda) SWOT analysis in Parkinson's disease
Figure 2: Drug assessment summary for Azilect in Parkinson's disease
Figure 3: Drug assessment summary for Azilect in Parkinson's disease
List of Tables
Table 1: Azilect (rasagiline; Teva/Lundbeck/Takeda) - drug profile
Table 2: Pivotal Phase III clinical trial data for Azilect (rasagiline; Teva/Lundbeck/Takeda) in Parkinson's disease
For more information about this report visit https://www.researchandmarkets.com/research/d3smnw/azilect.